Hopeful Results of Coronavirus Vaccine in American Trial
The first phase of an American trial for an experimental corona vaccine produced hopeful results.
Pharmaceutical Moderna reported that all 45 subjects who entered the Phase 1 study developed antibodies that could “neutralize” the lung virus.
People involved in the trial received three doses of the vaccine. With each subsequent injection, the immune system could act more vigorously against the virus.
The level of antibodies in the blood was similar to that of corona patients recovered from Covid-19, the preliminary results showed.
The vaccine, called mRNA-1273, was otherwise relatively safe and caused minor side effects, the pharmacist said.
The next phase of the trial is expected to begin in July.
If the vaccine ultimately proves itself useful, it can get approval from the US healthcare authorities relatively quickly. They previously granted an accelerated approval procedure to Moderna.
